Men on TRT: What Every Patient Needs to Know About Testosterone Replacement Therapy

What Is TRT and Who Actually Qualifies?

Testosterone replacement therapy is FDA-approved specifically for men with hypogonadism, defined as consistently low serum testosterone combined with signs or symptoms such as reduced libido, fatigue, loss of muscle mass, or erectile dysfunction. Diagnosis requires two morning fasting testosterone measurements below 300 ng/dL on separate days, per the 2018 Endocrine Society Clinical Practice Guideline. [1]

Roughly 2.1% of men aged 40 to 79 have symptomatic androgen deficiency, though prevalence rises sharply with age, obesity, and chronic disease. [2] The guideline specifies that TRT should not be started based on a single low value, because testosterone secretion is pulsatile and levels fluctuate by up to 35% across the day.

Available formulations include daily transdermal gels (testosterone 1% or 1.62%), intramuscular injections of testosterone cypionate or enanthate (typically 100 to 200 mg every one to two weeks), subcutaneous pellets implanted every three to six months, and a nasal gel (Natesto 4.5% applied three times daily). Each route carries different pharmacokinetics, adherence profiles, and risk considerations. Your prescriber's formulation choice depends on your lifestyle, comorbidities, and fertility intentions.

Two morning total testosterone measurements below 300 ng/dL, combined with at least one reproducible symptom, are the minimum threshold before initiating therapy. [1] Starting on symptoms alone is not supported by evidence and increases the chance of treating a man whose low energy or reduced libido has a different cause entirely.

How TRT Affects Sexual Function and Quality of Life

Sexual benefits are the most studied outcome of TRT in hypogonadal men. A 2016 randomized controlled trial, the Testosterone Trials (TTrials, N=790 men aged 65 and older with testosterone below 275 ng/dL), found that testosterone gel significantly improved sexual desire and sexual activity compared with placebo over 12 months (P<0.001). [3]

Beyond libido, TRT's effects extend across several domains. Energy and mood tend to improve within four to six weeks. Lean muscle mass increases measurably by three months, while body fat changes take six to twelve months to become clinically significant. [1]

Erectile function responds more variably. Men whose ED stems primarily from low testosterone show improvement, but men with concurrent vascular disease, diabetes, or neurological injury often need phosphodiesterase-5 inhibitors (sildenafil, tadalafil) alongside TRT. The TTrials sexual function trial showed a modest but statistically significant improvement on the IIEF erectile function domain, confirming TRT alone is not a complete ED treatment for all men. [3]

Bone mineral density is another measurable benefit. The TTrials bone trial found that testosterone increased volumetric bone mineral density at the spine by 7.5% over 12 months compared with placebo. [4]

TRT and Cardiovascular Safety: What the TRAVERSE Trial Settled

For years, a 2010 pilot trial and a 2013 observational study raised concern that TRT might increase the risk of heart attacks and strokes. The 2024 TRAVERSE trial (N=5,204) resolved much of that uncertainty. TRAVERSE was a randomized, double-blind, placebo-controlled cardiovascular outcomes trial designed specifically to assess major adverse cardiovascular events (MACE) in men with hypogonadism and pre-existing cardiovascular disease or elevated cardiovascular risk. [5]

The primary endpoint was non-inferiority on MACE. Testosterone therapy was non-inferior to placebo (7.0% TRT vs. 7.3% placebo; hazard ratio 0.96 to 95% CI 0.78 to 1.17). [5] Following TRAVERSE, the FDA in 2024 updated labeling for all approved testosterone products to remove prior language about a possible increased risk of MACE. This is a meaningful regulatory change, not a minor footnote.

The FDA's updated prescribing information now states: "Results from the TRAVERSE cardiovascular outcomes trial demonstrated that testosterone replacement therapy did not increase the risk of major adverse cardiovascular events compared with placebo in men with hypogonadism." [6]

One safety signal did emerge. TRAVERSE identified a higher rate of atrial fibrillation (3.5% TRT vs. 2.4% placebo) and pulmonary embolism (0.9% vs. 0.5%) in the testosterone arm. [5] Men with a personal or family history of thromboembolic events or arrhythmia should discuss this finding with their cardiologist before starting TRT.

Erythrocytosis remains the most common manageable safety concern, with hematocrit rising above 54% in roughly 7% of men on injection-based TRT. Monitoring hematocrit at 3, 6, and 12 months, and annually thereafter, is standard of care. [1]

TRT in Men With Diabetes: Metabolic Benefits and Monitoring Priorities

Low testosterone and type 2 diabetes share a bidirectional relationship. Hypogonadism worsens insulin resistance, and hyperglycemia suppresses luteinizing hormone and testosterone production. Breaking this cycle with TRT may offer metabolic benefits beyond symptom relief.

A 2016 randomized controlled trial by Dhindsa et al. (N=178 men with type 2 diabetes and hypogonadism) showed that intramuscular testosterone undecanoate reduced HbA1c by 0.87 percentage points and fasting glucose by 1.58 mmol/L compared with placebo at 30 weeks. [7] Insulin sensitivity, measured by HOMA-IR, also improved significantly (P<0.001). [7]

The TRAVERSE metabolic substudy further showed that TRT reduced the incidence of new-onset type 2 diabetes in men with prediabetes by 12% compared with placebo over a median of 21.7 months, though this finding requires confirmation in longer trials. [5]

Practical monitoring points for men with diabetes on TRT include checking HbA1c at three and six months after initiation, because improved insulin sensitivity may require downward adjustment of antidiabetic medication doses. Sulfonylureas and insulin carry hypoglycemia risk when insulin sensitivity suddenly improves. Inform your diabetes prescriber the moment you start TRT.

Weight is another variable. TRT reduced body weight by a mean of 1.7 kg versus 0.3 kg for placebo in TRAVERSE, a modest effect, but one that compounds beneficially over time in men already managing metabolic syndrome. [5]

TRT in Men With Benign Prostatic Hyperplasia

BPH and low testosterone frequently coexist in men over 50, which creates a clinical dilemma: will TRT worsen urinary obstructive symptoms by stimulating prostate growth? The concern is understandable, but the evidence is reassuring for carefully selected patients.

A 2015 systematic review in the Journal of Urology (examining 14 RCTs, N<700 combined) found no clinically meaningful change in prostate volume or International Prostate Symptom Score (IPSS) in hypogonadal men treated with TRT for up to 12 months compared with placebo. [8] Prostate-specific antigen (PSA) rose modestly, averaging 0.3 ng/mL above baseline, which reflects restoration of normal androgen-driven PSA production rather than pathological growth. [8]

The AUA's Benign Prostatic Hyperplasia Guidelines recommend obtaining a baseline IPSS, PSA, and post-void residual urine volume before starting TRT in men with known BPH, then repeating IPSS at 3 and 6 months. [9] A rise in IPSS of 3 or more points warrants re-evaluation and possible urology referral.

Men on 5-alpha reductase inhibitors (finasteride, dutasteride) for BPH present a specific consideration. These drugs reduce DHT, the primary androgen driving prostate growth. TRT co-administered with a 5-ARI may blunt the prostate-stimulating effect of exogenous testosterone, though this combination has not been studied in large randomized trials. [1]

The following decision framework summarizes monitoring for TRT candidates with BPH and is intended for use by HealthRX clinicians during the intake and follow-up workflow:

Pre-TRT BPH Checklist

1. Baseline PSA (two values if borderline 2.5 to 4.0 ng/mL)
2. Baseline IPSS questionnaire
3. Post-void residual by bladder scan if IPSS above 15
4. Urology co-management if PSA above 4.0 ng/mL or IPSS above 20
5. Re-check PSA, IPSS, and hematocrit at 3 months post-initiation

Absolute contraindications to TRT in the BPH setting include untreated bladder outlet obstruction with post-void residual above 200 mL and active urothelial malignancy.

TRT After Prostate Surgery: Navigating a High-Stakes Decision

Radical prostatectomy for localized prostate cancer removes the primary androgen-responsive tissue of concern, which has led some oncologists and urologists to reconsider the longstanding absolute ban on post-surgical TRT. The Endocrine Society's guideline previously listed "history of prostate cancer" as a contraindication; updated expert opinion has shifted toward a case-by-case approach in carefully selected low-risk patients. [1]

A 2015 systematic review by Pastuszak et al. examined 11 studies of TRT after radical prostatectomy in men with confirmed undetectable or stable PSA (total N=232). Biochemical recurrence rates ranged from 0 to 3.8%, which were not meaningfully different from recurrence rates observed in age-matched post-prostatectomy men not receiving TRT. [10]

The cautious standard remains a PSA nadir of 0.0 ng/mL confirmed on at least two successive measurements, a waiting period of 1 to 2 years post-surgery, and a pre-operative Gleason score of 7 or below (preferably 6). [10] Men with Gleason 8 to 10 disease, positive surgical margins, seminal vesicle involvement, or rising PSA after surgery are not candidates for TRT at this time.

Erectile dysfunction after prostatectomy is nearly universal in the first year. Nerve-sparing techniques preserve erectile function in approximately 50 to 80% of men by 18 months, depending on surgical skill and bilateral versus unilateral sparing. [11] For men who are hypogonadal post-prostatectomy, restoring testosterone may improve the response to PDE5 inhibitors, as testosterone is required for nitric oxide synthase activity in penile smooth muscle. [3]

Penile rehabilitation, typically with daily low-dose tadalafil 5 mg, is recommended by many urologists starting six to eight weeks post-surgery, regardless of TRT status. Early oxygenation of penile tissue preserves smooth muscle architecture and reduces the risk of permanent corporal fibrosis. [11]

Initiating TRT: Lab Workup, Formulation Selection, and Follow-Up

Getting TRT right begins before the first dose. A complete baseline panel should include total and free testosterone (morning, fasting, two separate draws), LH and FSH (to distinguish primary from secondary hypogonadism), CBC, comprehensive metabolic panel, PSA, SHBG, estradiol, and hematocrit. [1] Prolactin is checked if secondary hypogonadism is suspected, as pituitary adenoma can masquerade as idiopathic low testosterone.

Formulation selection affects both efficacy and lifestyle:

Testosterone cypionate or enanthate IM/SQ injection: 100 mg weekly or 200 mg biweekly. Cost-effective, well-studied, but creates peak-trough hormone swings that some men find uncomfortable.

Testosterone gel 1.62% (AndroGel, Testim): 40.5 to 81 mg applied daily. Stable serum levels, but transfer risk to partners and children requires hand-washing and covering the application site.

Testosterone pellets (Testopel): 150 to 450 mg subcutaneous implant every 3 to 6 months. High adherence, no daily maintenance, but dose cannot be adjusted between insertions.

Natesto nasal gel: 4.5% testosterone, 11 mg per nostril three times daily. Preserves gonadotropin pulsatility and has the best fertility-preservation data among TRT options. [12]

Follow-up labs at 3 months after initiation should include total testosterone (trough for injections, 2 to 8 hours post-application for gels), hematocrit, PSA, and a symptom review using a validated scale such as the Aging Male Symptom (AMS) questionnaire. Annual monitoring thereafter covers the same panel plus a lipid profile and bone density (DEXA) every two years in men with baseline osteopenia.

Fertility Considerations: TRT Suppresses Sperm Production

Exogenous testosterone suppresses the hypothalamic-pituitary-gonadal axis. LH and FSH drop within weeks, and intratesticular testosterone, the primary driver of spermatogenesis, falls by more than 90%. [12] Men who want to father children should not use conventional TRT formulations.

Alternatives that preserve or restore fertility include clomiphene citrate (Clomid, 25 to 50 mg every other day), which stimulates endogenous testosterone by blocking estrogen receptors at the pituitary, and human chorionic gonadotropin (hCG, 500 to 1 to 000 IU subcutaneous two to three times weekly), which mimics LH and directly stimulates Leydig cell testosterone production. [12] Some protocols combine low-dose TRT with hCG to maintain intratesticular testosterone while still providing systemic hormone replacement.

Recovery of spermatogenesis after stopping TRT averages 3 to 6 months, but in some men, particularly those on TRT for longer than 2 years, recovery may take 12 months or require FSH supplementation. [12]

Side Effects and How to Manage Them

TRT's side effect profile is manageable when monitoring protocols are followed. The most clinically relevant issues are:

Erythrocytosis: Hematocrit above 54% occurs in 7 to 10% of men on injectable TRT, less commonly with transdermal routes. The fix is dose reduction, formulation switch to gel or nasal, or therapeutic phlebotomy. [1]

Estradiol elevation: Testosterone aromatizes to estradiol, and in men with higher adipose tissue, levels can rise enough to cause gynecomastia or fluid retention. An estradiol level above 42.6 pg/mL combined with symptoms may warrant low-dose anastrozole (0.5 to 1 mg twice weekly), though routine aromatase inhibitor use is not endorsed by the Endocrine Society. [1]

Testicular atrophy: Gonadotropin suppression reduces testicular volume. Co-administration of hCG 500 IU twice weekly largely prevents this. [12]

Acne and oily skin: Responds to standard dermatological management. More common with injectable testosterone due to higher peak levels.

Sleep apnea worsening: TRT may worsen obstructive sleep apnea. A baseline Epworth Sleepiness Scale and, in high-risk men, a sleep study before initiation is appropriate. [1]